Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278488 (
metastatic breast cancer
)
7,812
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Since 1989 we have been collecting dry-platelets on a routine basis. Dry-platelets are those collected along with 25-30 ml of contaminating plasma cell with separators such as the Amicus, AS 104 and the Excel Pro. Platelets are resuspended in non plasma media for storage and for at least 60 hours their viability and functionality are not impaired. In this article we report on two hemolytic crises determined by two O Rh D + units of single donor platelets (
SPD
) taken from the same donor in a double-apheresis session. The two split units were administered to two A Rh D + patients suffering from
metastatic breast cancer
and severe aplastic anemia (SAA) respectively. In both cases the hemolytic reaction was of the intravascular type, with a drop in hemoglobin (Hgb) level from 8.6 to 5.4 and from 8.8 down to 5.3 g/dl respectively. From the patients' RBC only alpha agglutinins were eluted and donor's indirect antiglobulin test (IAT) was negative with extended panel RBCs. In the first case the clinical course after erythroexchange (Erex) was uneventful whereas in the second one, that suffering from SAA, after Erex, acute renal failure and shock did complicate the clinical course and the patient died seven days after the incriminated platelet transfusion.
...
PMID:Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor. 1105 88
The leading causes of death in breast cancer patients are disease recurrence and metastasis. Growing evidence has suggested that metastasis possibly originates from cancer stem-like cells (CSCs). Previous studies indicated dopamine decreased CSC frequency through activating dopamine D
1
receptor pathway. Hence, this study explored the efficacy of two dopamine D
1
receptor agonists in lung metastasis of breast cancer and the preliminary mechanism. The two dopamine D
1
receptor agonists, fenoldopam (FEN) and l-stepholidine (l-SPD), performed well in decreasing lung metastasis in 4T1 breast cancer model. And the cGMP in the primary tumor was significantly elevated while cAMP mildly elevated in FEN and l-
SPD
dosing groups. CSC markers (CD44
+
/CD24
-
and ALDH
+
) and MMP2 in 4T1 primary tumor were repressed after dopamine D
1
receptor agonist administration while E-cadherin up-regulated. FEN and l-
SPD
also inhibited cancer stemness and cell motility in vitro, and the inhibitory effects could be reversed by dopamine D
1
receptor antagonist SCH23390. Besides, FEN impacted the white blood cell increase caused by breast cancer disease showing decreased neutrophils but increased lymphocytes. Drug safety was verified in aspects of body weight, organ index and tissue section. In conclusion, dopamine D
1
receptor agonists FEN and l-
SPD
showed efficacy in inhibiting metastasis along with good safety in breast cancer, thus providing an alternative for anti-metastasis therapy in the future. Furthermore, this study also indicates that dopamine D
1
receptor may be a possible target for
metastatic breast cancer
treatment and even other cancers at a late stage.
...
PMID:Dopamine D
1
receptor agonists inhibit lung metastasis of breast cancer reducing cancer stemness. 3124 39
